 |
An experimental oral drug being tested for multiple sclerosis, called teriflunomide (Sanofi-Aventis), significantly reduced MRI-detected disease activity in a 36-week, Phase II clinical trial involving 179 people with relapsing MS.
Teriflunomide is an agent that may modulate T cells, which drive the immune attack in MS. Paul O’Connor, MD (University of Toronto) and colleagues originally reported these results at the 2004 Congress of the European Committee for Treatment and Research in MS, and have now published the findings in Neurology (2006 Mar 28;66(6):894-900).
Dr. O’Connor and his team recruited 157 people with relapsing-remitting MS (characterized by clearly defined flare-ups followed by partial or complete recovery periods), and 22 people with secondary-progressive MS (a secondary stage of the disease involving a steadily worsening course, occurring with or without relapses) with relapses.
To read more, please follow the weblink below.
Source: US National MS Society
Weblink: click here
|
